2 assets in Esophageal Melanoma

Therapeutic assets addressing Esophageal Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Esophageal Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Esophageal Melanoma	National Cancer Institute (NCI)	P2	CCC (53)